- Home
- ALKT vs CPRX Comparison
ALKT vs CPRX Comparison
Compare ALKT & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALKT
- CPRX
- Stock Information
- Founded
- ALKT 2007
- CPRX 2002
- Country
- ALKT United States
- CPRX United States
- Employees
- ALKT N/A
- CPRX N/A
- Industry
- ALKT EDP Services
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- ALKT Technology
- CPRX Health Care
- Exchange
- ALKT Nasdaq
- CPRX Nasdaq
- Market Cap
- ALKT 2.6B
- CPRX 2.9B
- IPO Year
- ALKT 2021
- CPRX 2006
- Fundamental
- Price
- ALKT $21.31
- CPRX $23.68
- Analyst Decision
- ALKT Buy
- CPRX Strong Buy
- Analyst Count
- ALKT 8
- CPRX 5
- Target Price
- ALKT $35.88
- CPRX $32.60
- AVG Volume (30 Days)
- ALKT 1.9M
- CPRX 1.4M
- Earning Date
- ALKT 10-30-2025
- CPRX 11-05-2025
- Dividend Yield
- ALKT N/A
- CPRX N/A
- EPS Growth
- ALKT N/A
- CPRX 44.94
- EPS
- ALKT N/A
- CPRX 1.71
- Revenue
- ALKT $412,504,000.00
- CPRX $578,196,000.00
- Revenue This Year
- ALKT $35.49
- CPRX $16.59
- Revenue Next Year
- ALKT $23.99
- CPRX $8.42
- P/E Ratio
- ALKT N/A
- CPRX $13.71
- Revenue Growth
- ALKT 30.72
- CPRX 25.56
- 52 Week Low
- ALKT $18.71
- CPRX $19.05
- 52 Week High
- ALKT $41.77
- CPRX $26.58
- Technical
- Relative Strength Index (RSI)
- ALKT 49.26
- CPRX 69.16
- Support Level
- ALKT $20.76
- CPRX $22.23
- Resistance Level
- ALKT $21.86
- CPRX $23.92
- Average True Range (ATR)
- ALKT 0.85
- CPRX 0.80
- MACD
- ALKT 0.28
- CPRX 0.09
- Stochastic Oscillator
- ALKT 81.36
- CPRX 91.23
About ALKT Alkami Technology Inc.
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company's solution, the Alkami Digital Banking Platform, allows FIs to onboard and engage new users, accelerate revenues and meaningfully improve operational efficiency, all with the support of a proprietary, true cloud-based, multi-tenant architecture.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).